The global pneumococcal vaccine market is forecast to grow at a CAGR of nearly 4.0% during the forecast period. Increasing individual, governmental, and international organization expenditure on the pneumococcal vaccine to curb the pneumonia is a major factor for the growth of the market in the near future. Few market players have a major market share in the pneumococcal vaccine all across the globe which includes Pfizer Inc., Sanofi SA, and GlaxoSmithKline PLC.
A full report of Pneumococcal Vaccine Market is available at: https://www.omrglobal.com/industry-reports/pneumococcal-vaccine-market
Pfizer is the market leader in the pneumococcal vaccine market. The company offers the pneumococcal vaccine under the brand name Prevnar 13. It first got the European Union approval in December 2009 and then the US FDA approval in February 2010. In 2019, the company generated $5.8 billion from the sales of Prevnar 13. Out of the total revenue, around $3.2 billion was generated from the US alone.
Merck & Co., Inc. is another major company offering vaccines all across the globe. The company offers Pneumovax 23. The vaccine has generated revenue of $926 million in 2019 as compared to $907 million and $821 million in 2018 and 2017 respectively. GlaxoSmithKline PLC is another major player in the pneumococcal vaccine. The company is offering Synflorix against pneumonia all across the globe except the US. The vaccine has generated revenue of more than $580 million in 2019 compared to more than $430 million in 2018. The company also offers its vaccines to 10 Gavi-eligible countries at a discounted price. The company has pledged to deliver 720 million doses of Synflorix.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/pneumococcal-vaccine-market
However, new players are also entering the market which can end the monopoly of the companies in the global market. For instance, in January 2020, a Chinese company Walvax Biotechnology Co., Ltd. got the pneumococcal 13-valent conjugate vaccine approval from the National Medical Products Administration. It is the first pneumococcal 13-valent conjugate vaccine developed which can affect the revenue of Pfizer Inc. In 2018, about 3.85 million doses of Prevnar 13 were sold in China whereas Walva is planning to produce around 30 million doses in a year. Moreover, in December 2019, India based Serum Institute of India also developed a 10-valent pneumococcal vaccine and got WHO approvals.
However, the major players are also significantly working to develop new products. For instance, Pfizer Inc. is working to develop a vaccine against all 20 serotypes of pneumonia disease. Merck & Co., Inc. is also working on the V114 polyvalent conjugate 15-valent pneumococcal vaccine. Phase 3 of the vaccine was initiated in June 2018 in adults over 50 years and on pediatric were initiated in October 2018. In June 2020, the company got success in two phases 3 trials of the vaccine. Due to multiple activities, a considerable disruption in the revenue of the companies will be witnessed in the near future which are dealing in the pneumococcal vaccine industry.
Global Pneumococcal Vaccine Market- Segmentation
By Vaccine Type
- Pneumococcal Conjugate Vaccine (PCV13)
- Pneumococcal Polysaccharide Vaccine (PPSV23)
- Others
By Distribution Channel
- Public
- Private
By Type
- Branded
- Generic
By Age Group
- Children
- Adult
Global Pneumococcal Vaccine Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Astellas Pharma Inc.
- China National Biotec Group Company Ltd.
- CSL Ltd.
- GlaxoSmithKline PLC
- Merck & Co., Inc.
- Novavax, Inc.
- Pfizer Inc.
- Walvax Biotechnology Co., Ltd.
- SK Bioscience
- Sanofi SA
- Serum Institute of India Pvt. Ltd.
- PnuVax Incorporated
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404
